Literature DB >> 1650523

Tumour necrosis factor production in a rat airpouch model of inflammation: role of eicosanoids.

M L Ferrándiz1, S J Foster.   

Abstract

TNF is a potent cytokine which can induce many of the pathological changes associated with inflammatory disease. In vitro studies have demonstrated that 5-lipoxygenase products promote the production of TNF by activated macrophages, suggesting that 5-lipoxygenase inhibitors may have therapeutic utility for the treatment of inflammatory conditions. A rat airpouch model of inflammation has been used to investigate the relationship between eicosanoid generation and TNF production in vivo. Injection of zymosan into the airpouch caused a time-dependent stimulation of TNF production which preceded leukotriene generation by at least 30 minutes. Injection of LPS into the airpouch also stimulated TNF production but not leukotriene generation. The selective 5-lipoxygenase inhibitors, ICI207968, A64077 and BWA4C, and the 5-lipoxygenase translocation inhibitor MK886, decreased leukotriene generation but enhanced TNF production. Taken together, these results do not support a role for 5-lipoxygenase products in the regulation of TNF production in vivo.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1650523     DOI: 10.1007/bf01980888

Source DB:  PubMed          Journal:  Agents Actions        ISSN: 0065-4299


  23 in total

1.  Lipoxygenase inhibitors suppress formation of tumor necrosis factor in vitro and in vivo.

Authors:  U F Schade; M Ernst; M Reinke; D T Wolter
Journal:  Biochem Biophys Res Commun       Date:  1989-03-15       Impact factor: 3.575

2.  2-substituted indazolinones: orally active and selective 5-lipoxygenase inhibitors with anti-inflammatory activity.

Authors:  S J Foster; P Bruneau; E R Walker; R M McMillan
Journal:  Br J Pharmacol       Date:  1990-01       Impact factor: 8.739

3.  Inhibitory effect of TNF alpha antibodies on synovial cell interleukin-1 production in rheumatoid arthritis.

Authors:  F M Brennan; D Chantry; A Jackson; R Maini; M Feldmann
Journal:  Lancet       Date:  1989-07-29       Impact factor: 79.321

4.  L-663,536 (MK-886) (3-[1-(4-chlorobenzyl)-3-t-butyl-thio-5-isopropylindol-2-yl]-2,2 - dimethylpropanoic acid), a novel, orally active leukotriene biosynthesis inhibitor.

Authors:  J Gillard; A W Ford-Hutchinson; C Chan; S Charleson; D Denis; A Foster; R Fortin; S Leger; C S McFarlane; H Morton
Journal:  Can J Physiol Pharmacol       Date:  1989-05       Impact factor: 2.273

5.  Asbestos fibers and silica particles stimulate rat alveolar macrophages to release tumor necrosis factor. Autoregulatory role of leukotriene B4.

Authors:  C M Dubois; E Bissonnette; M Rola-Pleszczynski
Journal:  Am Rev Respir Dis       Date:  1989-05

6.  Modulation of tumor necrosis factor-alpha gene expression. Desensitization of prostaglandin E2-induced suppression.

Authors:  R N Spengler; M L Spengler; R M Strieter; D G Remick; J W Larrick; S L Kunkel
Journal:  J Immunol       Date:  1989-06-15       Impact factor: 5.422

7.  Inflammation induced by bacterial cell wall fragments in the rat air pouch. Comparison of rat strains and measurement of arachidonic acid metabolites.

Authors:  S Yoshino; W J Cromartie; J H Schwab
Journal:  Am J Pathol       Date:  1985-11       Impact factor: 4.307

8.  Leukotrienes augment interleukin 1 production by human monocytes.

Authors:  M Rola-Pleszczynski; I Lemaire
Journal:  J Immunol       Date:  1985-12       Impact factor: 5.422

9.  Regulation of monokine gene expression: prostaglandin E2 suppresses tumor necrosis factor but not interleukin-1 alpha or beta-mRNA and cell-associated bioactivity.

Authors:  W E Scales; S W Chensue; I Otterness; S L Kunkel
Journal:  J Leukoc Biol       Date:  1989-05       Impact factor: 4.962

10.  Antibodies to cachectin/tumor necrosis factor reduce interleukin 1 beta and interleukin 6 appearance during lethal bacteremia.

Authors:  Y Fong; K J Tracey; L L Moldawer; D G Hesse; K B Manogue; J S Kenney; A T Lee; G C Kuo; A C Allison; S F Lowry
Journal:  J Exp Med       Date:  1989-11-01       Impact factor: 14.307

View more
  7 in total

1.  Mechanisms underlying the anti-inflammatory activity and gastric safety of acemetacin.

Authors:  A E Chávez-Piña; W McKnight; M Dicay; G Castañeda-Hernández; J L Wallace
Journal:  Br J Pharmacol       Date:  2007-09-17       Impact factor: 8.739

2.  COX-2 expression and function in the hyperalgesic response to paw inflammation in mice.

Authors:  Naveen K Jain; Tomo-o Ishikawa; Igor Spigelman; Harvey R Herschman
Journal:  Prostaglandins Leukot Essent Fatty Acids       Date:  2008-10-01       Impact factor: 4.006

3.  Tumour necrosis factor alpha production by rat blood and its ex vivo pharmacological modulation.

Authors:  S J Foster; L M McCormick
Journal:  Agents Actions       Date:  1993

4.  Production of TNF alpha by LPS-stimulated murine, rat and human blood and its pharmacological modulation.

Authors:  S J Foster; L M McCormick; B A Ntolosi; D Campbell
Journal:  Agents Actions       Date:  1993

5.  Inhibition of tumor necrosis factor-alpha action within the CNS markedly reduces the plasma adrenocorticotropin response to peripheral local inflammation in rats.

Authors:  A V Turnbull; F J Pitossi; J J Lebrun; S Lee; J C Meltzer; D M Nance; A del Rey; H O Besedovsky; C Rivier
Journal:  J Neurosci       Date:  1997-05-01       Impact factor: 6.167

Review 6.  The use of rodent models to investigate host-bacteria interactions related to periodontal diseases.

Authors:  Dana T Graves; Daniel Fine; Yen-Tung A Teng; Thomas E Van Dyke; George Hajishengallis
Journal:  J Clin Periodontol       Date:  2008-02       Impact factor: 8.728

7.  Involvement of secretory phospholipase A2 activity in the zymosan rat air pouch model of inflammation.

Authors:  M Payá; M C Terencio; M L Ferrándiz; M J Alcaraz
Journal:  Br J Pharmacol       Date:  1996-04       Impact factor: 8.739

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.